LGALS9 and hematopoietic and lymphoid cell neoplasm: Conversely, in hematological cancers, high Gal-9 expression correlated with more rapid disease progression, as reflected by progression-free survival (PFS) or time to treatment (TTT) (HR =  2.29, 95% CI: 1.26–4.16, p =  0.007).